Publications

  1. Lech PJ, Pappoe R, Nakamura T, Russell SJ. Antibody neutralization of retargeted measles viruses. Virology. 2014 Apr; 454-455C:237-46. Epub 2014 Mar 14.
    View PubMed
  2. Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Vesiculovirus neutralization by natural IgM and complement. J Virol. 2014 Mar 19.
    View PubMed
  3. Liu YP, Wang J, Avanzato VA, Bakkum-Gamez JN, Russell SJ, Bell JC, Peng KW. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol. 2014 Mar; 132(3):722-9. Epub 2014 Jan 14.
    View PubMed
  4. Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2014 Mar; 89(3):302-5. Epub 2014 Feb 18.
    View PubMed
  5. Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Vincent Rajkumar S, Dispenzieri A. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol. 2014 Feb 6. [Epub ahead of print]
    View PubMed
  6. Jing Y, Zaias J, Duncan R, Russell SJ, Merchan JR. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models. Gene Ther. 2014 Mar; 21(3):289-97. Epub 2014 Jan 16.
    View PubMed
  7. Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):194-202. Epub 2013 Nov 15
    View PubMed
  8. Liu YP, Russell SP, Ayala-Breton C, Russell SJ, Peng KW. Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus. J Virol. 2014 Feb; 88(4):2195-204. Epub 2013 Dec 11.
    View PubMed
  9. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013 Dec 20; 31(36):4529-35. Epub 2013 Nov 18.
    View PubMed
  10. Yarde DN, Naik S, Nace RA, Peng KW, Federspiel MJ, Russell SJ. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV. Cancer Gene Ther. 2013 Nov; 20(11):616-21. Epub 2013 Nov 01.
    View PubMed
  11. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013 Oct 25.
    View PubMed
  12. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122(26):4172-81. Epub 2013 Oct 21.
    View PubMed
  13. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013 Dec 1; 31(34):4319-24. Epub 2013 Oct 21.
    View PubMed
  14. Ammayappan A, Peng KW, Russell SJ. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol. 2013 Dec; 87(24):13543-55. Epub 2013 Oct 02.
    View PubMed
  15. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines. 2013 Oct; 12(10):1155-72.
    View PubMed
  16. Yarde DN, Nace RA, Russell SJ. Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo. Exp Hematol. 2013 Dec; 41(12):1038-49. Epub 2013 Sep 22.
    View PubMed
  17. Suksanpaisan L, Pham L, McIvor S, Russell SJ, Peng KW. Oral contrast enhances the resolution of in-life NIS reporter gene imaging. Cancer Gene Ther. 2013 Nov; 20(11):638-41. Epub 2013 Sep 13.
    View PubMed
  18. Escobar-Zarate D, Liu YP, Suksanpaisan L, Russell SJ, Peng KW. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors. Cancer Gene Ther. 2013 Oct; 20(10):582-9. Epub 2013 Sep 13.
    View PubMed
  19. Bailey K, Kirk A, Naik S, Nace R, Steele MB, Suksanpaisan L, Li X, Federspiel MJ, Peng KW, Kirk D, Russell SJ. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PLoS One. 2013; 8(9):e73759. Epub 2013 Sep 11.
    View PubMed
  20. Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther. 2013 Aug; 20(8):478-85. Epub 2013 Jul 19.
    View PubMed
  21. Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW, Hui KM. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 2013 Nov; 59(5):999-1006. Epub 2013 Jul 16.
    View PubMed
  22. Ayala-Breton C, Suksanpaisan L, Mader EK, Russell SJ, Peng KW. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol Ther. 2013 Oct; 21(10):1930-7. Epub 2013 Jul 11.
    View PubMed
  23. Touchefeu Y, Khan AA, Borst G, Zaidi SH, McLaughlin M, Roulstone V, Mansfield D, Kyula J, Pencavel T, Karapanagiotou EM, Clayton J, Federspiel MJ, Russell SJ, Garrett M, Collins I, Harrington KJ. Optimising measles virus-guided radiovirotherapy with external beam radiotherapy and specific checkpoint kinase 1 inhibition. Radiother Oncol. 2013 Jul; 108(1):24-31. Epub 2013 Jul 09.
    View PubMed
  24. Geng L, Gao Y, Chen X, Hou S, Zhan CG, Radic Z, Parks RJ, Russell SJ, Pham L, Brimijoin S. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS One. 2013; 8(6):e67446. Epub 2013 Jun 28.
    View PubMed
  25. Leung N, Glavey SV, Kumar S, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Gertz MA. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica. 2013 Jun; 98(6):988-92.
    View PubMed
  26. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013 Jul 4; 122(1):68-73. Epub 2013 May 22.
    View PubMed
  27. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, Kumar S. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 2013 Oct; 27(10):2062-6. Epub 2013 May 07.
    View PubMed
  28. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88(4):360-76.
    View PubMed
  29. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013 May; 88(5):375-8. Epub 2013 Mar 19.
    View PubMed
  30. Liu C, Suksanpaisan L, Chen YW, Russell SJ, Peng KW. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol. 2013 Jun; 41(6):508-17. Epub 2013 Feb 08.
    View PubMed
  31. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013; 11:20. Epub 2013 Jan 24.
    View PubMed
  32. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol. 2013 Apr; 87(7):3752-9. Epub 2013 Jan 16.
    View PubMed
  33. Lech PJ, Tobin GJ, Bushnell R, Gutschenritter E, Pham LD, Nace R, Verhoeyen E, Cosset FL, Muller CP, Russell SJ, Nara PL. Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One. 2013; 8(1):e52306. Epub 2013 Jan 03.
    View PubMed
  34. Ammayappan A, Nace R, Peng KW, Russell SJ. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol. 2013 Mar; 87(6):3217-28. Epub 2013 Jan 02.
    View PubMed
  35. Liu YP, Suksanpaisan L, Steele MB, Russell SJ, Peng KW. Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci Rep. 2013; 3:2375.
    View PubMed
  36. Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C, Studebaker AW. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer. 2012; 12:508. Epub 2012 Nov 07.
    View PubMed
  37. Ruiz A, Russell SJ. A new paradigm in viral resistance. Cell Res. 2012 Nov; 22(11):1515-7. Epub 2012 Oct 02.
    View PubMed
  38. Mori MA, Raghavan P, Thomou T, Boucher J, Robida-Stubbs S, Macotela Y, Russell SJ, Kirkland JL, Blackwell TK, Kahn CR. Role of microRNA processing in adipose tissue in stress defense and longevity. Cell Metab. 2012 Sep 5; 16(3):336-47.
    View PubMed
  39. Penheiter AR, Dingli D, Bender CE, Russell SJ, Carlson SK. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. J Gene Med. 2012 Sep-Oct; 14(9-10):590-7.
    View PubMed
  40. Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC 3rd, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther. 2012 Sep; 19(9):659-65. Epub 2012 Jul 13.
    View PubMed
  41. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012 Jul; 30(7):658-70. Epub 2012 Jul 10.
    View PubMed
  42. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, Greipp PR, Hayman SR, Kumar SK, Lust JA, Russell SJ, Witzig TE, Mikhael J, Leung N, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012 Jul; 87(7):647-51. Epub 2012 May 02.
    View PubMed
  43. Naik S, Nace R, Barber GN, Russell SJ. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther. 2012 Jul; 19(7):443-50. Epub 2012 Apr 20.
    View PubMed
  44. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012 May 24; 119(21):4860-7. Epub 2012 Apr 13.
    View PubMed
  45. Peng KW, Myers R, Greenslade A, Mader E, Greiner S, Federspiel MJ, Dispenzieri A, Russell SJ. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther. 2013 Mar; 20(3):255-61. Epub 2012 Apr 05.
    View PubMed
  46. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012 Jun 7; 119(23):5397-404. Epub 2012 Apr 04.
    View PubMed
  47. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. Curative one-shot systemic virotherapy in murine myeloma. Leukemia. 2012 Aug; 26(8):1870-8. Epub 2012 Mar 19.
    View PubMed
  48. Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, Russell SJ, Galanis E. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther. 2012 Jun; 20(6):1139-47. Epub 2012 Feb 14.
    View PubMed
  49. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20; 30(9):989-95. Epub 2012 Feb 13.
    View PubMed
  50. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther. 2012 May; 23(5):484-91. Epub 2012 Feb 07.
    View PubMed
  51. Studebaker AW, Hutzen B, Pierson CR, Russell SJ, Galanis E, Raffel C. Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol. 2012 Apr; 14(4):459-70. Epub 2012 Feb 03.
    View PubMed
  52. Penheiter AR, Russell SJ, Carlson SK. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012 Feb 1; 12(1):33-47.
    View PubMed
  53. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum Gene Ther. 2012 Mar; 23(3):295-301. Epub 2012 Jan 11.
    View PubMed
  54. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012 Mar 1; 119(9):2100-5. Epub 2012 Jan 10.
    View PubMed
  55. Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E. Oncolytic measles virus retargeting by ligand display. Methods Mol Biol. 2012; 797:141-62.
    View PubMed
  56. Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, Peach H, Phillips RM, Bond J, Pandha H, Harrington K, Vile R, Russell S, Selby P, Melcher AA. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013 Jan; 20(1):7-15. Epub 2011 Dec 15.
    View PubMed
  57. Liu YP, Tong C, Dispenzieri A, Federspiel MJ, Russell SJ, Peng KW. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther. 2012 Mar; 19(3):202-11. Epub 2011 Nov 25.
    View PubMed
  58. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol. 2012 Feb; 156(3):326-33. Epub 2011 Nov 23.
    View PubMed
  59. Gertz MA, Buadi FK, Hayman SR, Dingli D, Dispenzieri A, Greipp PR, Kumar SK, Lacy MQ, Lust JA, Leung N, Rajkumar SV, Russell SJ, Zeldenrust SR, Mikhael JR, Roy V, Kyle RA. Immunoglobulin D amyloidosis: a distinct entity. Blood. 2012 Jan 5; 119(1):44-8. Epub 2011 Nov 07.
    View PubMed
  60. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, Kyle RA, Kumar S, Greipp PR, Lust JA, Russell SJ, Zeldenrust S, Dingli D, Witzig TE, Rajkumar SV, Dispenzieri A. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011 Oct 27; 118(17):4663-5. Epub 2011 Aug 31.
    View PubMed
  61. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther. 2012 Mar; 19(3):279-87. Epub 2011 Jul 14.
    View PubMed
  62. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011 Sep 15; 118(11):2970-5. Epub 2011 Jun 20.
    View PubMed
  63. Hadac EM, Federspiel MJ, Chernyy E, Tuzikov A, Korchagina E, Bovin NV, Russell S, Henry SM. Fluorescein and radiolabeled Function-Spacer-Lipid constructs allow for simple in vitro and in vivo bioimaging of enveloped virions. J Virol Methods. 2011 Sep; 176(1-2):78-84. Epub 2011 Jun 14.
    View PubMed
  64. Russell SJ, Rajkumar SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol. 2011 Jul; 12(7):617-9. Epub 2011 Jun 12.
    View PubMed
  65. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol. 2011 Aug; 86(8):640-5. Epub 2011 May 31.
    View PubMed
  66. Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 2011 Jun; 26(6):2032-6. Epub 2011 May 04.
    View PubMed
  67. Hadac EM, Kelly EJ, Russell SJ. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. Mol Ther. 2011 Jun; 19(6):1041-7. Epub 2011 Apr 19.
    View PubMed
  68. Frecha C, Levy C, Costa C, Negre D, Amirache F, Buckland R, Russell SJ, Cosset FL, Verhoeyen E. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol. 2011 Jun; 85(12):5975-85. Epub 2011 Mar 30.
    View PubMed
  69. Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC Jr, Ikeda Y. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation. 2011 Mar 29; 123(12):1297-305. Epub 2011 Mar 14.
    View PubMed
  70. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc. 2011 Jan; 86(1):12-8.
    View PubMed
  71. Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ, Goel A. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia. 2010 Dec; 12(12):980-92.
    View PubMed
  72. Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines. 2010 Nov; 9(11):1275-302.
    View PubMed
  73. Detweiler-Short K, Hayman S, Gertz MA, Lacy MQ, Dispenzieri A, Kumar S, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Greipp PR, Witzig TE, Vincent Rajkumar S. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am J Hematol. 2010 Oct; 85(10):737-40.
    View PubMed
  74. Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S, Buadi F, Zeldenrust S, Leung N, Detweiler-Short K, Lust JA, Russell SJ, Kyle RA, Gertz MA. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010 Oct; 85(10):757-9.
    View PubMed
  75. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010 Nov; 24(11):1934-9. Epub 2010 Sep 9
    View PubMed
  76. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85(9):824-33. Epub 2010 Aug 11.
    View PubMed
  77. Ennis MK, Hu C, Naik SK, Hallak LK, Peng KW, Russell SJ, Dingli D. Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entry. J Virol. 2010 Oct; 84(20):10913-7. Epub 2010 Aug 11.
    View PubMed
  78. Penheiter AR, Wegman TR, Classic KL, Dingli D, Bender CE, Russell SJ, Carlson SK. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol. 2010 Aug; 195(2):341-9.
    View PubMed
  79. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, Witzig TE, Lacy MQ, Zeldenrust SR, Rajkumar SV, Russell SJ, Hayman SR, Buadi F, Kumar SK, Dingli D, Dispenzieri A. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011 Jan; 90(1):101-6. Epub 2010 Jul 20.
    View PubMed
  80. Ricci D, Mennander AA, Miyagi N, Rao VP, Tazelaar HD, Classic K, Byrne GW, Russell SJ, McGregor CG. Prolonged cardiac allograft survival using iodine 131 after human sodium iodide symporter gene transfer in a rat model. Transplant Proc. 2010 Jun; 42(5):1888-94.
    View PubMed
  81. Studebaker AW, Kreofsky CR, Pierson CR, Russell SJ, Galanis E, Raffel C. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010 Oct; 12(10):1034-42. Epub 2010 May 21.
    View PubMed
  82. Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010 Aug; 17(8):550-8. Epub 2010 Apr 09.
    View PubMed
  83. Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther. 2010 Apr; 21(4):451-62.
    View PubMed
  84. Kelly EJ, Hadac EM, Cullen BR, Russell SJ. MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog. 2010 Mar; 6(3):e1000820. Epub 2010 Mar 19.
    View PubMed
  85. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther. 2010 Jun; 18(6):1155-64. Epub 2010 Mar 16.
    View PubMed
  86. Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lonnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul; 47(1):12-22. Epub 2010 Mar 15.
    View PubMed
  87. Senac JS, Doronin K, Russell SJ, Jelinek DF, Greipp PR, Barry MA. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010 Feb; 21(2):179-90.
    View PubMed
  88. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View PubMed
  89. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26.
    View PubMed
  90. Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther. 2010 Jan; 21(1):51-64.
    View PubMed
  91. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010 Feb 18; 115(7):1343-50. Epub 2009 Dec 11.
    View PubMed
  92. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009 Dec; 84(12):1095-110.
    View PubMed
  93. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009 Dec 1; 15(23):7246-55. Epub 2009 Nov 24.
    View PubMed
  94. Kelly EJ, Nace R, Barber GN, Russell SJ. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol. 2010 Feb; 84(3):1550-62. Epub 2009 Nov 11.
    View PubMed
  95. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat. 2010 Aug; 122(3):745-54. Epub 2009 Nov 06.
    View PubMed
  96. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther. 2009 Dec; 17(12):2041-8. Epub 2009 Sep 22.
    View PubMed
  97. Naik S, Russell SJ. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther. 2009 Sep; 9(9):1163-76.
    View PubMed
  98. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20; 27(30):5008-14. Epub 2009 Aug 31.
    View PubMed
  99. Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A, Salles G, Peng KW, Cosset FL, Verhoeyen E. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood. 2009 Oct 8; 114(15):3173-80. Epub 2009 Aug 10.
    View PubMed
  100. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate. 2009 Jul 1; 69(10):1128-41.
    View PubMed
  101. Peng KW, Dogan A, Vrana J, Liu C, Ong HT, Kumar S, Dispenzieri A, Dietz AB, Russell SJ. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol. 2009 Jul; 84(7):401-7.
    View PubMed
  102. Dingli D, Offord C, Myers R, Peng KW, Carr TW, Josic K, Russell SJ, Bajzer Z. Dynamics of multiple myeloma tumor therapy with a recombinant measles virus. Cancer Gene Ther. 2009 Dec; 16(12):873-82. Epub 2009 Jun 05.
    View PubMed
  103. Iankov ID, Hillestad ML, Dietz AB, Russell SJ, Galanis E. Converting tumor-specific markers into reporters of oncolytic virus infection. Mol Ther. 2009 Aug; 17(8):1395-403. Epub 2009 May 26.
    View PubMed
  104. Gertz MA, Leung N, Lacy MQ, Dispenzieri A, Zeldenrust SR, Hayman SR, Buadi FK, Dingli D, Greipp PR, Kumar SK, Lust JA, Rajkumar SV, Russell SJ, Witzig TE. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant. 2009 Oct; 24(10):3132-7. Epub 2009 Apr 29.
    View PubMed
  105. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26.
    View PubMed
  106. Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther. 2009 Jun; 17(6):1012-21. Epub 2009 Mar 10.
    View PubMed
  107. Pham L, Nakamura T, Gabriela Rosales A, Carlson SK, Bailey KR, Peng KW, Russell SJ. Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome. J Gene Med. 2009 Mar; 11(3):197-206.
    View PubMed
  108. Schmeckpeper J, Ikeda Y, Kumar AH, Metharom P, Russell SJ, Caplice NM. Lentiviral tracking of vascular differentiation in bone marrow progenitor cells. Differentiation. 2009 Sep-Oct; 78(2-3):169-76. Epub 2009 Feb 20.
    View PubMed
  109. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica. 2009 Mar; 94(3):380-6. Epub 2009 Feb 11.
    View PubMed
  110. Jing Y, Tong C, Zhang J, Nakamura T, Iankov I, Russell SJ, Merchan JR. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res. 2009 Feb 15; 69(4):1459-68. Epub 2009 Feb 10.
    View PubMed
  111. Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009 Feb; 84(2):114-22.
    View PubMed
  112. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate. 2009 Jan 1; 69(1):82-91.
    View PubMed
  113. Carlson SK, Classic KL, Hadac EM, Dingli D, Bender CE, Kemp BJ, Russell SJ. Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene. AJR Am J Roentgenol. 2009 Jan; 192(1):279-87.
    View PubMed
  114. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol. 2009; 330:213-41.
    View PubMed
  115. Russell SJ. Manipulating miRNA responsiveness to decrease viral pathogenicity. Future Virol. 2009; 4(1):19-21.
    View PubMed
  116. Kelly EJ, Russell SJ. MicroRNAs and the regulation of vector tropism. Mol Ther. 2009 Mar; 17(3):409-16. Epub 2008 Dec 23.
    View PubMed
  117. Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Kumar S, Kyle RA, Fonseca R, Greipp PR, Lust JA, Rajkumar VS, Hayman SR, Buadi F, Russell SJ, Zeldenrust SR, Dispenzieri A. A novel report of cig-FISH and cytogenetics in POEMS syndrome. Am J Hematol. 2008 Nov; 83(11):840-1.
    View PubMed
  118. Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008 Nov; 14(11):1278-83. Epub 2008 Oct 26.
    View PubMed
  119. Russell SJ, Peng KW. The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther. 2008 Aug; 10(4):380-6.
    View PubMed
  120. Allen C, Paraskevakou G, Iankov I, Giannini C, Schroeder M, Sarkaria J, Schroeder M, Puri RK, Russell SJ, Galanis E. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther. 2008 Sep; 16(9):1556-64. Epub 2008 Jul 29.
    View PubMed
  121. Blechacz B, Russell SJ. Measles virus as an oncolytic vector platform. Curr Gene Ther. 2008 Jun; 8(3):162-75.
    View PubMed
  122. Miyagi N, Rao VP, Ricci D, Du Z, Byrne GW, Bailey KR, Nakai H, Russell SJ, McGregor CG. Efficient and durable gene transfer to transplanted heart using adeno-associated virus 9 vector. J Heart Lung Transplant. 2008 May; 27(5):554-60.
    View PubMed
  123. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008 Jun; 73(11):1282-8. Epub 2008 Apr 02.
    View PubMed
  124. Han YJ, Loo SC, Phung NT, Ong HT, Russell SJ, Peng KW, Boey F, Ma J. Controlled size and morphology of EDTMP-doped hydroxyapatite nanoparticles as model for 153Samarium-EDTMP doping. J Mater Sci Mater Med. 2008 Sep; 19(9):2993-3003. Epub 2008 Mar 25.
    View PubMed
  125. Munguia A, Ota T, Miest T, Russell SJ. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 2008 May; 15(10):797-806. Epub 2008 Mar 20.
    View PubMed
  126. Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I, Russell SJ, Galanis E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther. 2008 Jul; 15(14):1024-34. Epub 2008 Mar 20.
    View PubMed
  127. Bajzer Z, Carr T, Josic K, Russell SJ, Dingli D. Modeling of cancer virotherapy with recombinant measles viruses. J Theor Biol. 2008 May 7; 252(1):109-22. Epub 2008 Feb 01.
    View PubMed
  128. Ong HT, Loo JSC, Boey FYC, Russell SJ, Ma J, Peng KW. Exploiting the high-affinity phosphonate-hydroxyapatite nanoparticle interaction for delivery of radiation and drugs. Journal of Nanoparticle Research. 2008 Feb; 10(1):141-50.
    View PubMed
  129. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther. 2008 Feb; 8(2):213-20.
    View PubMed
  130. Rao VP, Miyagi N, Ricci D, Carlson SK, Morris JC 3rd, Federspiel MJ, Bailey KR, Russell SJ, McGregor CG. Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation. Transplantation. 2007 Dec 27; 84(12):1662-6.
    View PubMed
  131. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res. 2007 Dec 1; 13(23):7155-65.
    View PubMed
  132. Rao VP, Branzoli SE, Ricci D, Miyagi N, O'Brien T, Tazelaar HD, Russell SJ, McGregor CG. Recombinant adenoviral gene transfer does not affect cardiac allograft vasculopathy. J Heart Lung Transplant. 2007 Dec; 26(12):1281-5.
    View PubMed
  133. Ricci D, Mennander AA, Pham LD, Rao VP, Miyagi N, Byrne GW, Russell SJ, McGregor CG. Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts. Eur J Cardiothorac Surg. 2008 Jan; 33(1):32-9. Epub 2007 Nov 05.
    View PubMed
  134. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008 Mar 1; 111(5):2516-20. Epub 2007 Nov 01.
    View PubMed
  135. Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, Reid JM, Federspiel M, Ames MM, Dingli D, Schweikart K, Welch A, Dispenzieri A, Peng KW, Russell SJ. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther. 2007 Dec; 82(6):700-10. Epub 2007 Oct 31.
    View PubMed
  136. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82(10):1179-84.
    View PubMed
  137. Doyle B, Kemp BJ, Chareonthaitawee P, Reed C, Schmeckpeper J, Sorajja P, Russell S, Araoz P, Riederer SJ, Caplice NM. Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J Nucl Med. 2007 Oct; 48(10):1708-14.
    View PubMed
  138. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007 Dec; 81(23):13149-57. Epub 2007 Sep 05.
    View PubMed
  139. Waehler R, Russell SJ, Curiel DT. Engineering targeted viral vectors for gene therapy. Nat Rev Genet. 2007 Aug; 8(8):573-87. Epub 2007 Jul 03.
    View PubMed
  140. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007 Jul; 28(7):326-33. Epub 2007 Jun 18.
    View PubMed
  141. Goel A, Carlson SK, Classic KL, Greiner S, Naik S, Power AT, Bell JC, Russell SJ. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. 2007 Oct 1; 110(7):2342-50. Epub 2007 May 21.
    View PubMed
  142. Schirmer JM, Miyagi N, Rao VP, Ricci D, Federspiel MJ, Kotin RM, Russell SJ, McGregor CG. Recombinant adeno-associated virus vector for gene transfer to the transplanted rat heart. Transpl Int. 2007 Jun; 20(6):550-7. Epub 2007 Apr 02.
    View PubMed
  143. Carlson SK, Classic KL, Bender CE, Russell SJ. Small animal absorbed radiation dose from serial micro-computed tomography imaging. Mol Imaging Biol. 2007 Mar-Apr; 9(2):78-82.
    View PubMed
  144. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82(3):323-41.
    View PubMed
  145. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther. 2007 Apr; 15(4):677-86. Epub 2007 Feb 13.
    View PubMed
  146. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
  147. Haralambieva I, Iankov I, Hasegawa K, Harvey M, Russell SJ, Peng KW. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther. 2007 Mar; 15(3):588-97. Epub 2007 Jan 16.
    View PubMed
  148. Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ, Caplice N, Russell SJ. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther. 2007 Jan; 15(1):114-22.
    View PubMed
  149. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 2006 Dec 15; 66(24):11840-50.
    View PubMed
  150. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ, Russell SJ, LaRusso NF. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology. 2006 Dec; 44(6):1465-77.
    View PubMed
  151. Carlson SK, Classic KL, Hadac EM, Bender CE, Kemp BJ, Lowe VJ, Hoskin TL, Russell SJ. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol. 2006 Nov-Dec; 8(6):324-32.
    View PubMed
  152. Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007 Feb; 14(4):324-33. Epub 2006 Oct 19.
    View PubMed
  153. Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 Jan 15; 109(2):465-70. Epub 2006 Sep 28.
    View PubMed
  154. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol. 2006 Sep; 80(17):8530-40.
    View PubMed
  155. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81(8):1047-53.
    View PubMed
  156. Oi K, Davies WR, Tazelaar HD, Bailey KR, Federspiel MJ, Russell SJ, McGregor CG. Ex vivo hypothermic recirculatory adenoviral gene transfer to the transplanted pig heart. J Gene Med. 2006 Jul; 8(7):795-803.
    View PubMed
  157. Szecsi J, Drury R, Josserand V, Grange MP, Boson B, Hartl I, Schneider R, Buchholz CJ, Coll JL, Russell SJ, Cosset FL, Verhoeyen E. Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther. 2006 Nov; 14(5):735-44. Epub 2006 Jun 19.
    View PubMed
  158. Merchan JR, Tang J, Hu G, Lin Y, Mutter W, Tong C, Karumanchi SA, Russell SJ, Sukhatme VP. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst. 2006 Jun 7; 98(11):756-64.
    View PubMed
  159. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ, Peng KW. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006 Jun; 34(6):713-20.
    View PubMed
  160. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat. 2006 Sep; 99(2):177-84. Epub 2006 Apr 27.
    View PubMed
  161. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res. 2006 Mar 15; 12(6):1868-75.
    View PubMed
  162. Peng KW, Hadac EM, Anderson BD, Myers R, Harvey M, Greiner SM, Soeffker D, Federspiel MJ, Russell SJ. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 2006 Aug; 13(8):732-8. Epub 2006 Mar 10.
    View PubMed
  163. Goel A, Dispenzieri A, Geyer SM, Greiner S, Peng KW, Russell SJ. Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood. 2006 May 15; 107(10):4063-70. Epub 2006 Jan 19.
    View PubMed
  164. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107(8):3378-83. Epub 2006 Jan 05.
    View PubMed
  165. Dingli D, Kemp BJ, O'Connor MK, Morris JC, Russell SJ, Lowe VJ. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol. 2006 Jan-Feb; 8(1):16-23.
    View PubMed
  166. Goel A, Dispenzieri A, Witzig TE, Russell SJ. Enhancing the therapeutic index of radiation in multiple myeloma. Drug Discovery Today: Disease Mechanisms. 2006; 3(4):515-22.
    View PubMed
  167. Dingli D, Cascino MD, Josic K, Russell SJ, Bajzer Z. Mathematical modeling of cancer radiovirotherapy. Math Biosci. 2006 Jan; 199(1):55-78. Epub 2005 Dec 22.
    View PubMed
  168. Dingli D, Peng KW, Harvey ME, Vongpunsawad S, Bergert ER, Kyle RA, Cattaneo R, Morris JC, Russell SJ. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun. 2005 Nov 11; 337(1):22-9.
    View PubMed
  169. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15; 106(13):4050-3. Epub 2005 Aug 23.
    View PubMed
  170. Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, Blanco MC, Frisk CS, Marler RJ, Davis BJ, O'Connor MK, Russell SJ, Morris JC. A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther. 2005 Nov; 12(5):835-41. Epub 2005 Jul 27.
    View PubMed
  171. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol. 2005 Jul; 33(7):784-95.
    View PubMed
  172. Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K, Shaw A, Rozenblatt S, Federspiel MJ, Russell SJ, Peng KW. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005 Jul; 12(7):593-9.
    View PubMed
  173. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res. 2005 Jun 15; 65(12):5292-300.
    View PubMed
  174. Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther. 2005 Jun; 12(11):918-26.
    View PubMed
  175. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IAJ, James CD, Russell SJ. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005 Feb; 23(2):209-14.
    View PubMed
  176. Dingli D, Bergert ER, Bajzer Z, O'connor MK, Russell SJ, Morris JC. Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter. Biochem Biophys Res Commun. 2004 Dec 3; 325(1):157-66.
    View PubMed
  177. Hadac EM, Peng KW, Nakamura T, Russell SJ. Reengineering paramyxovirus tropism. Virology. 2004 Nov 24; 329(2):217-25.
    View PubMed
  178. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. J Gene Med. 2004 Nov; 6(11):1216-27.
    View PubMed
  179. Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opinion on Biological Therapy. 2004 Oct; 4(10):1685-92.
    View PubMed
  180. Zhang J, Frolov I, Russell SJ. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein. J Gene Med. 2004 Oct; 6(10):1082-91.
    View PubMed
  181. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor. Gene Ther. 2004 Aug; 11(15):1234-9.
    View PubMed
  182. Blechacz B, Russell SJ. Parvovirus vectors: use and optimisation in cancer gene therapy. Expert Rev Mol Med. 2004 Jul 23; 6(16):1-24.
    View PubMed
  183. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004 Jul 15; 64(14):4919-26.
    View PubMed
  184. Doran PM, Turner RT, Chen D, Facteau SM, Ludvigson JM, Khosla S, Riggs BL, Russell SJ. Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol. 2004 Apr; 32(4):351-9.
    View PubMed
  185. Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T, Cattaneo R, Russell SJ. Antibody-targeted cell fusion. Nat Biotechnol. 2004 Mar; 22(3):331-6.
    View PubMed
  186. Dingli D, Russell SJ, Morris JC 3rd. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem. 2003 Dec 15; 90(6):1079-86.
    View PubMed
  187. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, Morris JC, Russell SJ. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004 Mar 1; 103(5):1641-6. Epub 2003 Nov 06.
    View PubMed
  188. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther. 2003 Nov 1; 14(16):1565-77.
    View PubMed
  189. Russell SJ, Peng KW. Primer on medical genomics. Part X: Gene therapy. Mayo Clin Proc. 2003 Nov; 78(11):1370-83.
    View PubMed
  190. Khare PD, Russell SJ, Federspiel MJ. Avian leukosis virus is a versatile eukaryotic platform for polypeptide display. Virology. 2003 Oct 25; 315(2):303-12.
    View PubMed
  191. Khare PD, Rosales AG, Bailey KR, Russell SJ, Federspiel MJ. Epitope selection from an uncensored peptide library displayed on avian leukosis virus. Virology. 2003 Oct 25; 315(2):313-21.
    View PubMed
  192. Schneider RM, Medvedovska Y, Hartl I, Voelker B, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther. 2003 Aug; 10(16):1370-80.
    View PubMed
  193. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003 May 15; 63(10):2462-9.
    View PubMed
  194. Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. Gene Ther. 2003 May; 10(9):725-32.
    View PubMed
  195. Peng KW, Donovan KA, Schneider U, Cattaneo R, Lust JA, Russell SJ. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 2003 Apr 1; 101(7):2557-62.
    View PubMed
  196. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4754-9. Epub 2003 Mar 28.
    View PubMed
  197. Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ. Genetically targeted radiotherapy for multiple myeloma. Blood. 2003 Jul 15; 102(2):489-96. Epub 2003 Mar 20.
    View PubMed
  198. Khurana VG, Weiler DA, Witt TA, Smith LA, Kleppe LS, Parisi JE, Simari RD, O'Brien T, Russell SJ, Katusic ZS. A direct mechanical method for accurate and efficient adenoviral vector delivery to tissues. Gene Ther. 2003 Mar; 10(5):443-52.
    View PubMed
  199. Sandrin V, Russell SJ, Cosset FL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol. 2003; 281:137-78.
    View PubMed
  200. Fielding AK, Russell SJ. ABC of Clinical Haematology, Second Edition: The future of haematology: the impact of molecular biology and gene therapy. Brit Med J. 2003:65-70.
  201. Dingli D, Timm M, Russell SJ, Witzig TE, Rajkumar SV. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma. Clin Cancer Res. 2002 Dec; 8(12):3948-54.
    View PubMed
  202. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther. 2002 Dec; 9(12):961-6.
    View PubMed
  203. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002 Aug 15; 62(16):4656-62.
    View PubMed
  204. Sanz L, Kristensen P, Blanco B, Facteau S, Russell SJ, Winter G, Alvarez-Vallina L. Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. 2002 Aug; 9(15):1049-53.
    View PubMed
  205. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002 Jul; 8(7):2210-6.
    View PubMed
  206. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002 May; 8(5):527-31.
    View PubMed
  207. Maurice M, Verhoeyen E, Salmon P, Trono D, Russell SJ, Cosset FL. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002 Apr 1; 99(7):2342-50.
    View PubMed
  208. Larochelle A, Peng KW, Russell SJ. Lentiviral vector targeting. Curr Top Microbiol Immunol. 2002; 261:143-63.
    View PubMed
  209. Sanz L, Kristensen P, Russell SJ, Ramirez Garcia JR, Alvarez-Vallina L. Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol Immunother. 2001 Dec; 50(10):557-65.
    View PubMed
  210. Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. Br J Cancer. 2001 Nov 16; 85(10):1432-6.
    View PubMed
  211. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001 Oct 1; 98(7):2002-7.
    View PubMed
  212. Peng KW, Pham L, Ye H, Zufferey R, Trono D, Cosset FL, Russell SJ. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors. Gene Ther. 2001 Oct; 8(19):1456-63.
    View PubMed
  213. Lavillette D, Russell SJ, Cosset FL. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol. 2001 Oct; 12(5):461-6.
    View PubMed
  214. Russell SJ, Dunbar CE. Gene therapy approaches for multiple myeloma. Semin Hematol. 2001 Jul; 38(3):268-75.
    View PubMed
  215. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, Poland GA, Fielding AK. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 2001 Jun 15; 97(12):3746-54.
    View PubMed
  216. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001 Jun; 38(3):177-92.
    View PubMed
  217. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther. 2001 May 1; 12(7):811-21.
    View PubMed
  218. DasGupta SF, Rapoport SI, Gerschenson M, Murphy E, Fiskum G, Russell SJ, Chandrasekaran K. ATP synthesis is coupled to rat liver mitochondrial RNA synthesis. Mol Cell Biochem. 2001 May; 221(1-2):3-10.
    View PubMed
  219. Lavillette D, Boson B, Russell SJ, Cosset FL. Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein. J Virol. 2001 Apr; 75(8):3685-95.
    View PubMed
  220. Pham L, Ye H, Cosset FL, Russell SJ, Peng KW. Concentration of viral vectors by co-precipitation with calcium phosphate. J Gene Med. 2001 Mar-Apr; 3(2):188-94.
    View PubMed
  221. Hammond AL, Plemper RK, Zhang J, Schneider U, Russell SJ, Cattaneo R. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol. 2001 Mar; 75(5):2087-96.
    View PubMed
  222. Doran PM, Russell SJ. Gene therapy and women's health – A review. Postgraduate Obstetrics & Gynecology. 2001; 21(26):1-8.
  223. Gaken J, Jiang J, Daniel K, van Berkel E, Hughes C, Kuiper M, Darling D, Tavassoli M, Galea-Lauri J, Ford K, Kemeny M, Russell S, Farzaneh F. Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron. Gene Ther. 2000 Dec; 7(23):1979-85.
    View PubMed
  224. Grote D, Cornu T, Cattaneo R, Russell S, Fielding A. Live attenuated measles virus as a replicating virus therapy for non-Hodgkin's lymphoma. Blood. 2000 Nov 16; 96(11 Part 1):212a.
    View PubMed
  225. Schneider U, Bullough F, Vongpunsawad S, Russell SJ, Cattaneo R. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000 Nov; 74(21):9928-36.
    View PubMed
  226. Diaz RM, Bateman A, Emiliusen L, Fielding A, Trono D, Russell SJ, Vile RG. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 2000 Oct; 7(19):1656-63.
    View PubMed
  227. Fielding AK, Chapel-Fernandes S, Chadwick MP, Bullough FJ, Cosset FL, Russell SJ. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum Gene Ther. 2000 Apr 10; 11(6):817-26.
    View PubMed
  228. Alvarez-Vallina L, Yanez R, Blanco B, Gil M, Russell SJ. Pharmacologic suppression of target cell recognition by engineered T cells expressing chimeric T-cell receptors. Cancer Gene Ther. 2000 Apr; 7(4):526-9.
    View PubMed
  229. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ, Vile RG. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000 Mar 15; 60(6):1492-7.
    View PubMed
  230. Hatziioannou T, Russell SJ, Cosset FL. Incorporation of simian virus 5 fusion protein into murine leukemia virus particles and its effect on the co-incorporation of retroviral envelope glycoproteins. Virology. 2000 Feb 1; 267(1):49-57.
    View PubMed
  231. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Ther. 2000 Jan; 7(1):2-8.
    View PubMed
  232. Lavillette D, Ruggieri A, Russell SJ, Cosset FL. Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments. J Virol. 2000 Jan; 74(1):295-304.
    View PubMed
  233. Peng KW, Russell SJ. Viral vector targeting. Curr Opin Biotechnol. 1999 Oct; 10(5):454-7.
    View PubMed
  234. Russell SJ, Cosset FL. Modifying the host range properties of retroviral vectors. J Gene Med. 1999 Sep-Oct; 1(5):300-11.
    View PubMed
  235. Peng KW, Vile R, Cosset FL, Russell S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 1999 Sep; 6(9):1552-7.
    View PubMed
  236. Maurice M, Mazur S, Bullough FJ, Salvetti A, Collins MK, Russell SJ, Cosset FL. Efficient gene delivery to quiescent interleukin-2 (IL-2)-dependent cells by murine leukemia virus-derived vectors harboring IL-2 chimeric envelope glycoproteins. Blood. 1999 Jul 15; 94(2):401-10.
    View PubMed
  237. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther. 1999 Jun 10; 10(9):1533-44.
    View PubMed
  238. Alvarez-Vallina L, Russell SJ. Efficient discrimination between different densities of target antigen by tetracycline-regulatable T bodies. Hum Gene Ther. 1999 Mar 1; 10(4):559-63.
    View PubMed
  239. Russell SJ. Targeting at AACR American Association for Cancer Research, 90th Annual Meeting, April 10-14, 1999, Philadelphia. Tumor Targeting. 1999; 4(3):125-126.
  240. Chadwick MP, Morling FJ, Cosset F-L, Russell SJ. Modification of retroviral tropism by display of IGF-1. J Mol Biol. 1999; 285:485-94.
    View PubMed
  241. Russell ST, Gettman MT, Arndt CA, Nascimento AG, Kramer SA. Inguinal lipoblastomatosis in a male infant. J Urol. 1998 Dec; 160(6 Pt 1):2204.
    View PubMed
  242. Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol. 1998 Oct; 16(10):951-4.
    View PubMed
  243. Fielding AK, Maurice M, Morling FJ, Cosset FL, Russell SJ. Inverse targeting of retroviral vectors: selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells. Blood. 1998 Mar 1; 91(5):1802-9.
    View PubMed
  244. Peng KW, Morling FJ, Cosset FL, Russell SJ. Retroviral gene delivery system activatable by plasmin. Tumor Targeting. 1998; 3(2):112-120.
  245. Lavillette D, Maurice M, Roche C, Russell SJ, Sitbon M, Cosset F-L. A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes. J Virol. 1998; 72(12):9955-65.
    View PubMed
  246. Hatziiouannou T, Valsesia-Wittmann S, Russell SJ, Cosset F-L. Incorporation of fowl plague virus haemagglutinin into murine leukemia virus particles and analysis of the infectivity of thepseudotyped retroviruses. J Virol. 1998; 72:5313-7.
    View PubMed
  247. Martin F, Kupsch J, Takeuchi Y, Russell SJ, Cosset F-L, Collins MKL. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope. Human Gene Therapy. 1998; 9:737-46.
    View PubMed
  248. Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol. 1997 Dec 15; 159(12):5889-95.
    View PubMed
  249. Russell SJ. Science, medicine, and the future. Gene therapy. (Review). BMJ. 1997 Nov 15; 315(7118):1289-92.
    View PubMed
  250. Morling FJ, Peng KW, Cosset FL, Russell SJ. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology. 1997 Jul 21; 234(1):51-61.
    View PubMed
  251. Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin T, Oscier D, Zhu D, King C, Kumar S, Thompsett A, Stevenson GT. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther. 1997 Jul 1; 8(10):1287-99.
    View PubMed
  252. Fielding AK, Ager S, Russell SJ. ABC of clinical haematology. The future of haematology, molecular biology, and gene therapy. BMJ. 1997 May 10; 314(7091):1396-9.
    View PubMed
  253. Peng KW, Morling FJ, Cosset FL, Murphy G, Russell SJ. A gene delivery system activatable by disease-associated matrix metalloproteinases. Hum Gene Ther. 1997 Apr 10; 8(6):729-38.
    View PubMed
  254. Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset FL. Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding. EMBO J. 1997 Mar 17; 16(6):1214-23.
    View PubMed
  255. Fielding AK, Russell SJ. Gene therapy for B cell lymphomas. Cancer Surv. 1997; 30:327-42.
    View PubMed
  256. Brissinck J, Russell SJ. Vaccine strategies in non-Hodgkin's lymphomas. (Review). Baillieres Clin Haematol. 1996 Dec; 9(4):799-817.
    View PubMed
  257. Ager S, Nilson BH, Morling FJ, Peng KW, Cosset FL, Russell SJ. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther. 1996 Nov 10; 7(17):2157-64.
    View PubMed
  258. Cosset FL, Russell SJ. Targeting retrovirus entry. (Review). Gene Ther. 1996 Nov; 3(11):946-56.
    View PubMed
  259. Brandenburger A, Russell S. A novel packaging system for the generation of helper-free oncolytic MVM vector stocks. Gene Ther. 1996 Oct; 3(10):927-31.
    View PubMed
  260. Zhang J, Russell SJ. Vectors for cancer gene therapy. (Review). Cancer Metastasis Rev. 1996 Sep; 15(3):385-401.
    View PubMed
  261. Marin M, Noel D, Valsesia-Wittman S, Brockly F, Etienne-Julan M, Russell S, Cosset FL, Piechaczyk M. Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol. 1996 May; 70(5):2957-62.
    View PubMed
  262. Nilson BH, Morling FJ, Cosset FL, Russell SJ. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 1996 Apr; 3(4):280-6.
    View PubMed
  263. Valsesia-Wittmann S, Morling FJ, Nilson BH, Takeuchi Y, Russell SJ, Cosset FL. Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N terminus of Moloney murine leukemia virus SU. J Virol. 1996 Mar; 70(3):2059-64.
    View PubMed
  264. Russell SJ. Peptide-displaying phages for targeted gene delivery? Nat Med. 1996 Mar; 2(3):276-7.
    View PubMed
  265. Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology. 1995 Dec 1; 214(1):307-13.
    View PubMed
  266. Blaese M, Blankenstein T, Brenner M, Cohen-Haguenauer O, Gansbacher B, Russell S, Sorrentino B, Velu T. Vectors in cancer therapy: how will they deliver? (Review). Cancer Gene Ther. 1995 Dec; 2(4):291-7.
    View PubMed
  267. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol. 1995 Oct; 69(10):6314-22.
    View PubMed
  268. Morling FJ, Russell SJ. Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Ther. 1995 Sep; 2(7):504-8.
    View PubMed
  269. Vile RG, Russell SJ. Retroviruses as vectors. Br Med Bull. 1995 Jan; 51(1):12-30.
    View PubMed
  270. Russell SJ. Replicating vectors for cancer therapy: a question of strategy. (Review). Semin Cancer Biol. 1994 Dec; 5(6):437-43.
    View PubMed
  271. Khazaie K, Prifti S, Beckhove P, Griesbach A, Russell S, Collins M, Schirrmacher V. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci U S A. 1994 Aug 2; 91(16):7430-4.
    View PubMed
  272. Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther. 1994 Mar; 1(2):88-98.
    View PubMed
  273. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. (Review). Eur J Cancer. 1994; 30A(8):1165-71.
    View PubMed
  274. Hawkins RE, Russell SJ, Baier M, Winter G. The contribution of contact and non-contact residues of antibody in the affinity of binding to antigen. The interaction of mutant D1.3 antibodies with lysozyme. J Mol Biol. 1993 Dec 20; 234(4):958-64.
    View PubMed
  275. Kim TS, Russell SJ, Collins MK, Cohen EP. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens prolongs the survival of mice with melanoma. Int J Cancer. 1993 Nov 11; 55(5):865-72.
    View PubMed
  276. Patel PM, Flemming CL, Russell SJ, Eccles SA, Collins MK. Cytokine gene transfer as a therapeutic strategy. J Immunother. 1993 Nov; 14(4):310-3.
    View PubMed
  277. Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. A genetic approach to idiotypic vaccination. J Immunother. 1993 Nov; 14(4):273-8.
    View PubMed
  278. Patel PM, Flemming CL, Russell SJ, McKay IA, MacLennan KA, Box GM, Eccles SA, Collins MK. Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br J Cancer. 1993 Aug; 68(2):295-302.
    View PubMed
  279. Flemming CL, Russell SJ, Collins MK. Mutation of Asp20 of human interleukin-2 reveals a dual role of the p55 alpha chain of the interleukin-2 receptor. Eur J Immunol. 1993 Apr; 23(4):917-21.
    View PubMed
  280. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 1993 Mar 11; 21(5):1081-5.
    View PubMed
  281. Russell SJ. Gene therapy for cancer. The Cancer Journal. 1993; 6:21-5.
  282. Russell SJ, Llewelyn MB, Hawkins RE. Principles of antibody therapy. (Review). BMJ. 1992 Dec 5; 305(6866):1424-9.
    View PubMed
  283. Hawkins RE, Llewelyn MB, Russell SJ. Adapting antibodies for clinical use. (Review). BMJ. 1992 Nov 28; 305(6865):1348-52.
    View PubMed
  284. Llewelyn MB, Hawkins RE, Russell SJ. Discovery of antibodies. (Review). BMJ. 1992 Nov 21; 305(6864):1269-72.
    View PubMed
  285. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol. 1992 Aug 5; 226(3):889-96.
    View PubMed
  286. Kim TS, Russell SJ, Collins MK, Cohen EP. Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer. 1992 May 8; 51(2):283-9.
    View PubMed
  287. Russell SJ, Brandenburger A, Flemming CL, Collins MK, Rommelaere J. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol. 1992 May; 66(5):2821-8.
    View PubMed
  288. Russell SJ, Llewelyn MB, Hawkins RE. The human antibody library. BMJ. 1992 Mar 7; 304(6827):585-6.
    View PubMed
  289. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MK. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer. 1991 Jan 21; 47(2):244-51.
    View PubMed
  290. Brandenburger A, Russell SJ, Collins MKL, Rommelaere J. Transfer and selective expression of interleukin genes in neoplastic cells by means of recombinant parvoviruses. Human Gene Transfer. 1991; 219:285-6.
  291. Russell SJ. Lymphokine gene therapy for cancer. (Review). Immunol Today. 1990 Jun; 11(6):196-200.
    View PubMed
  292. Russell SJ. Recombinant viruses expressing lymphokine genes. Their construction and use to modulate growth of transplantable rodent tumours. PhD Thesis, University of London. 1990.
  293. Russell SJ, Flemming C, Eccles SA, Johnson C, Collins MKL. Transfer and expression of the human IL2 gene in a transplantable rat sarcoma. UCLA Symp Mol Cell Biol. 1990; 135:275-8.
  294. Russell SJ. Interleukin-2 and T cell malignancies: an autocrine loop with a twist. Leukemia. 1989 Oct; 3(10):755-7.
    View PubMed
  295. Russell SJ, Richards JD. Medical indications for splenectomy. (Review). Br J Hosp Med. 1989 Aug; 42(2):120-3, 125-6, 127.
    View PubMed
  296. Russell SJ, Giles FJ, Thompson DS, Scanlon DJ, Walker H, Richards JD. Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16). Cancer Genet Cytogenet. 1988 Oct 15; 35(2):231-5.
    View PubMed
  297. Russell SJ, Walker H, Giles FJ, Goldstone AH. Ring chromosome 6 and i(17q-) in a patient with acute promyelocytic leukemia. Absence of translocation t(15;17). Cancer Genet Cytogenet. 1988 Sep; 34(2):273-6.
    View PubMed
  298. Giles FJ, Russell SJ, Worman CP, Goldstone AH, Richards JD, Holton J. Atypical mycobacterial infection in alpha interferon-treated hairy cell leukaemia. Acta Haematol. 1988; 80(3):159-61.
    View PubMed
  299. Webster A, Russell SJ, Souhami RL, Richards JD, Goldstone AH, Gruneberg RN. Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients. J Hosp Infect. 1987 Jul; 10(1):77-82.
    View PubMed
  300. Russell SJ, Giles FJ, Edwards D, Porter J, Hardmann S, Harrison R. Perforation of superior vena cava by indwelling central venous catheters. Lancet. 1987 Mar 7; 1(8532):568-9.
    View PubMed
  301. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, Edwards G, Winstanley P. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986 Feb 22; 1(8478):411-4.
    View PubMed